Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2021

Nov 3, 2021

31100_dirs_2021-11-03_6a92d43d-9b3b-48d6-8b96-6bd342d21d0b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-11-01

Reporting Person: Sauer Paul (SVP Process Dev, Manufacturing)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-11-01 Common Stock S 3000 $25.00 Disposed 33125 Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.